These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19441912)

  • 21. Enhanced sensitivity to afferent stimulation and impact of overactive bladder therapies in the conscious, spontaneously hypertensive rat.
    Patra PB; Thorneloe KS
    J Pharmacol Exp Ther; 2011 Jul; 338(1):392-9. PubMed ID: 21521774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy of the overactive bladder.
    Andersson KE
    Discov Med; 2009 Oct; 8(42):118-24. PubMed ID: 19833057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fesoterodine (toviaz) for overactive bladder.
    Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
    Drinka PJ
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):292-3; author reply 293. PubMed ID: 17062331
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.
    Andersson KE; Chapple CR; Cardozo L; Cruz F; Hashim H; Michel MC; Tannenbaum C; Wein AJ
    Curr Opin Urol; 2009 Jul; 19(4):380-94. PubMed ID: 19448545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detrusor myocyte activity and afferent signaling.
    Andersson KE
    Neurourol Urodyn; 2010; 29(1):97-106. PubMed ID: 20025035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensory effects of antimuscarinics: still a matter of debate.
    Behr-Roussel D; Giuliano FA
    Eur Urol; 2010 Jul; 58(1):29-30. PubMed ID: 20083339
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Treating patients with overactive bladder symptoms with antimuscarinics; heart rate considerations.
    Wyllie MG
    BJU Int; 2008 Jan; 101(1):129. PubMed ID: 18086105
    [No Abstract]   [Full Text] [Related]  

  • 30. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations.
    Andersson KE; Olshansky B
    BJU Int; 2007 Nov; 100(5):1007-14. PubMed ID: 17922785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O
    Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Dmochowski R
    Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
    [No Abstract]   [Full Text] [Related]  

  • 35. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Speakman MJ
    Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
    [No Abstract]   [Full Text] [Related]  

  • 36. Antimuscarinic drugs to treat overactive bladder.
    Robinson D; Cardozo L
    BMJ; 2012 Mar; 344():e2130. PubMed ID: 22453185
    [No Abstract]   [Full Text] [Related]  

  • 37. Local effects of antimuscarinics.
    Masuda H; Kim YT; Tyagi S; Chancellor MB; de Miguel F; Yoshimura N
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
    Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
    BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overactive bladder: treatment options in primary care medicine.
    Sussman DO
    J Am Osteopath Assoc; 2007 Sep; 107(9):379-85. PubMed ID: 17908830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Substantiation of the duration of m-cholinolytics administration in conservative treatment of hyperactive urinary bladder].
    Danilov VV; Vol'nykh IIu; Danilova TI; Vodop'ianova OA; Kudriakova NA
    Urologiia; 2006; (5):71-4. PubMed ID: 17444156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.